Hinova Pharmaceuticals Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
241
- Stock Symbol
-
688302
- Investments
-
1
- Share Price
-
$4.57
- (As of Monday Closing)
Hinova Pharmaceuticals General Information
Description
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
Contact Information
Website
www.hinovapharma.comCorporate Office
- 4th Floor, Building 1, Rongyao Building
- No. 5, Keyuan South Road, High-tech Zone
- Chengdu, Sichuan 610041
- China
Corporate Office
- 4th Floor, Building 1, Rongyao Building
- No. 5, Keyuan South Road, High-tech Zone
- Chengdu, Sichuan 610041
- China
Hinova Pharmaceuticals Stock Performance
As of 16-Nov-2026, Hinova Pharmaceuticals’s stock price is $4.57. Its current market cap is $452M with 99M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.57 | $4.78 | $3.97 - $8.49 | $452M | 99M | 2.05M | -$0.20 |
Hinova Pharmaceuticals Financials Summary
As of 30-Sep-2026, Hinova Pharmaceuticals has a trailing 12-month revenue of $12.4M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 391,011 | 595,509 | 293,341 | 561,340 |
| Revenue | 12,437 | 2,846 | 51 | 0 |
| EBITDA | (20,761) | (19,190) | (28,291) | (42,173) |
| Net Income | (20,113) | (19,086) | (27,803) | (41,578) |
| Total Assets | 183,212 | 187,195 | 186,515 | 210,417 |
| Total Debt | 15,483 | 15,134 | 1,240 | 1,813 |
Hinova Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hinova Pharmaceuticals Comparisons
Industry
Financing
Details
Hinova Pharmaceuticals Competitors (3)
One of Hinova Pharmaceuticals’s 3 competitors is Haihe Biopharma, a Venture Capital-Backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Haihe Biopharma | Venture Capital-Backed | Shanghai, China | ||||
| Mabworks Biotech | Venture Capital-Backed | Beijing, China | ||||
| Innovent Biologics | Formerly VC-backed | Suzhou, China |
Hinova Pharmaceuticals Patents
Hinova Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026189052-A1 | Small-molecule compound as glp-1 receptor agonist and use thereof | Pending | 14-Mar-2025 | ||
| WO-2026145172-A1 | Heterocyclic compound, preparation method therefor, and use thereof in preparation of vav1 degradation agent | Pending | 31-Dec-2024 | ||
| WO-2026138908-A1 | Estrogen receptor degrading agent intermediates and preparation method therefor | Pending | 24-Dec-2024 | ||
| WO-2026123850-A1 | Salts of androgen receptor degrader, preparation method therefor and use thereof | Pending | 13-Dec-2024 | ||
| WO-2026073512-A1 | Heterocyclic compound, preparation method therefor, and use thereof for preparing glp-1 receptor agonist prodrug having oral pk characteristics and long-acting pk characteristics | Pending | 01-Oct-2024 |
Hinova Pharmaceuticals Signals
Hinova Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hinova Pharmaceuticals Investments (1)
Hinova Pharmaceuticals’s most recent deal was a Early Stage VC with MagicRNA. The deal was made on 29-Dec-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MagicRNA | 29-Dec-2022 | Early Stage VC | Drug Discovery |
Hinova Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Hinova Pharmaceuticals FAQs
-
When was Hinova Pharmaceuticals founded?
Hinova Pharmaceuticals was founded in 2013.
-
Where is Hinova Pharmaceuticals headquartered?
Hinova Pharmaceuticals is headquartered in Chengdu, China.
-
What is the size of Hinova Pharmaceuticals?
Hinova Pharmaceuticals has 241 total employees.
-
What industry is Hinova Pharmaceuticals in?
Hinova Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Hinova Pharmaceuticals a private or public company?
Hinova Pharmaceuticals is a Public company.
-
What is Hinova Pharmaceuticals’s stock symbol?
The ticker symbol for Hinova Pharmaceuticals is 688302.
-
What is the current stock price of Hinova Pharmaceuticals?
As of 16-Nov-2026 the stock price of Hinova Pharmaceuticals is $4.57.
-
What is the current market cap of Hinova Pharmaceuticals?
The current market capitalization of Hinova Pharmaceuticals is $452M.
-
What is Hinova Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Hinova Pharmaceuticals is $12.4M.
-
Who are Hinova Pharmaceuticals’s competitors?
Haihe Biopharma, Mabworks Biotech, and Innovent Biologics are competitors of Hinova Pharmaceuticals.
-
What is Hinova Pharmaceuticals’s annual earnings per share (EPS)?
Hinova Pharmaceuticals’s EPS for 12 months was -$0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process